Hebei Changshan Biochem Pharma (300255) — Tangible Net Worth Ratio
Hebei Changshan Biochem Pharma (300255) has a Tangible Net Worth Ratio of 48.3% as of September 2025. This metric is calculated by deducting intangible assets (CN¥764.41 Million) from net assets (CN¥1.48 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300255 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Hebei Changshan Biochem Pharma Tangible Net Worth Ratio (2008–2024)
This chart shows how Hebei Changshan Biochem Pharma's Tangible Net Worth Ratio has changed across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at 48.3%, reflecting net assets of CN¥1.48 Billion with intangible assets of CN¥764.41 Million CNY. See Hebei Changshan Biochem Pharma defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Hebei Changshan Biochem Pharma (2008–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Hebei Changshan Biochem Pharma (300255) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 52.1% | CN¥1.54 Billion | CN¥735.99 Million | CN¥4.52 Billion | ▼ -10.1 pp |
| 2023 | 62.2% | CN¥1.80 Billion | CN¥680.24 Million | CN¥4.60 Billion | ▼ -19.9 pp |
| 2022 | 82.1% | CN¥3.05 Billion | CN¥547.95 Million | CN¥6.04 Billion | ▼ -1.9 pp |
| 2021 | 83.9% | CN¥3.07 Billion | CN¥493.13 Million | CN¥5.19 Billion | ▼ -2.0 pp |
| 2020 | 85.9% | CN¥2.85 Billion | CN¥401.78 Million | CN¥4.57 Billion | ▼ -3.7 pp |
| 2019 | 89.7% | CN¥2.72 Billion | CN¥281.27 Million | CN¥3.94 Billion | ▲ +0.1 pp |
| 2018 | 89.5% | CN¥2.52 Billion | CN¥264.17 Million | CN¥3.84 Billion | ▼ -0.1 pp |
| 2017 | 89.7% | CN¥2.44 Billion | CN¥251.76 Million | CN¥3.53 Billion | ▼ -1.6 pp |
| 2016 | 91.3% | CN¥2.29 Billion | CN¥199.11 Million | CN¥3.13 Billion | ▼ -0.3 pp |
| 2015 | 91.6% | CN¥1.57 Billion | CN¥131.59 Million | CN¥2.33 Billion | ▲ +0.9 pp |
| 2014 | 90.8% | CN¥1.43 Billion | CN¥131.92 Million | CN¥2.04 Billion | ▲ +1.3 pp |
| 2013 | 89.5% | CN¥1.29 Billion | CN¥135.19 Million | CN¥1.65 Billion | ▼ -3.9 pp |
| 2012 | 93.4% | CN¥1.13 Billion | CN¥74.35 Million | CN¥1.42 Billion | ▼ -0.9 pp |
| 2011 | 94.3% | CN¥987.45 Million | CN¥56.06 Million | CN¥1.19 Billion | ▲ +20.5 pp |
| 2010 | 73.9% | CN¥219.39 Million | CN¥57.37 Million | CN¥430.64 Million | ▼ -8.8 pp |
| 2009 | 82.7% | CN¥159.19 Million | CN¥27.59 Million | CN¥266.35 Million | ▲ +12.9 pp |
| 2008 | 69.7% | CN¥93.43 Million | CN¥28.27 Million | CN¥196.59 Million | — |